Results 41 to 50 of about 1,113 (191)

Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]

open access: yes, 2016
Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core   +1 more source

Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien®) and follow-up considerations/ recommendations [PDF]

open access: yes, 2020
Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting ...
Abraldes, M.   +10 more
core   +3 more sources

Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases [PDF]

open access: yes, 2023
Purpose For the treatment of macular edema, in addition to the use of antivascular endothelial growth factors, steroids are also used intravitreally and sub-Tenon.
Abdin, Alaa Din   +4 more
core   +1 more source

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies

open access: yesDrug Design, Development and Therapy, 2023
Yusuf Mushtaq,1,* Maryam M Mushtaq,2,* Zisis Gatzioufas,3 Matteo Ripa,4 Lorenzo Motta,5 Georgios D Panos1 1Department of Ophthalmology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust & School of Medicine, University of ...
Mushtaq Y   +5 more
doaj  

The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema [PDF]

open access: yes, 2017
Aim: To assess the rate of ‘treatment-requiring diabetic macular oedema (DMO)’ in eyes for the two  years before and after cataract surgery. Methods: Multicentre national diabetic retinopathy (DR) database study with anonymised data extraction across ...
Akerele, T.   +25 more
core   +1 more source

ILUVIEN—A New Approach to the Treatment of Diabetic Macula Edema

open access: yesUS Ophthalmic Review, 2015
The antivascular endothelial growth factor (VEGF) ranibizumab (Lucentis) and aflibercept (EYLEA) and the intraocular corticosteroids dexamethasone (Ozurdex) and fluocinolone acetonide (ILUVIEN) are approved for treating diabetic macular edema (DME) in the US.
Richard Parrish, Pravin U Dugel
openaire   +1 more source

A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND) [PDF]

open access: yes, 2017
PURPOSE: The aim of this study was to assess the effectiveness and safety of ILUVIEN® in patients with chronic diabetic macular edema (DME) who were insufficiently responsive to prior therapies.
Alves, D   +5 more
core   +2 more sources

Scleral fixation of fluocinolone acetonide implant

open access: yesAmerican Journal of Ophthalmology Case Reports, 2020
Purpose: To report on the technique of scleral fixation of fluocinolone acetonide (FAc) implant in 2 eyes with recalcitrant diabetic macular edema (DME). Observations: Two eyes of 2 patients with persistent DME, partially responsive to anti-VEGF therapy,
Homayoun Tabandeh, Kourous Rezaei
doaj   +1 more source

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation [PDF]

open access: yes, 2022
The long-term effect of intravitreal Fluocinolone acetonide (FAc) on retinal morphology and function in diabetic macular edema (DME) was investigated. Seventeen eyes of twelve consecutive DME patients, treated by intravitreal FAc, were retrospectively ...
Falsini, Benedetto (ORCID:0000-0002-3569-4968)   +4 more
core   +1 more source

Dexamethasone Provides Effective Immunosuppression for Improved Survival of Retinal Organoids after Epiretinal Transplantation

open access: yesStem Cells International, Volume 2019, Issue 1, 2019., 2019
We investigated the efficacy of the immunosuppressants rapamycin (RAP) and dexamethasone (DEX) in improving the survival of retinal organoids after epiretinal transplantation. We first compared the immunosuppressive abilities of DEX and RAP in activated microglia in an in vitro setting.
Bikun Xian   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy